Clinical application of advances and innovation in radiation treatment of hepatocellular carcinoma

Hepatocellular carcinoma (HCC) has been one of the most highly lethal cancers. The acquisition of drug resistance accounts for the majority of poor effects of chemotherapy in HCC. Non-coding RNAs (ncRNAs) including miRNAs, long ncRNAs (lncRNAs), and circular RNA (circRNA) have been well-documented to participate in cancer occurrence and progression. Recently, multiple studies have highlighted the key roles of ncRNAs in chemoresistance of HCC. In addition, accumulating evidence has demonstrated that they can serve as biomarkers in diagnosis, treatment, and prognosis of HCC. In this review, we first overviewed up-to-date findings regarding miRNA and lncRNA in drug resistance of HCC, then summarized specific mechanisms that they modulate chemoresistance of HCC, and finally discussed their potential clinical application in overcoming the obstacle of HCC chemoresistance in the future.

Download Full-text

Role of alpha-fetoprotein in hepatitis B virus-induced hepatocellular carcinoma: Prospect in clinical application

World Chinese Journal of Digestology ◽

10.11569/wcjd.v23.i20.3171 ◽

2015 ◽

Vol 23 (20) ◽

pp. 3171

Author(s):

Chao Zhang

Keyword(s):

Hepatocellular Carcinoma ◽

Hepatitis B Virus ◽

Hepatitis B ◽

Clinical Application ◽

Alpha Fetoprotein ◽

B Virus

Download Full-text

Clinical application of cisplatin-phosphatidylcholine-lipiodol suspension for hepatocellular carcinoma.

The Japanese Journal of Pharmacology ◽

10.1016/s0021-5198(19)39287-x ◽

1991 ◽

Vol 55 ◽

pp. 300

Author(s):

Yoshiro Okano ◽

Yasuhiro Tomita ◽

Tsuyoshi Hashimoto ◽

Kenji Hirai ◽

Kyuichi Tanikawa ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Clinical Application

Download Full-text

Radiosensitisation of Hepatocellular Carcinoma Cells by Vandetanib

Cancers ◽

10.3390/cancers12071878 ◽

2020 ◽

Vol 12 (7) ◽

pp. 1878 ◽

Cited By ~ 2

Author(s):

Sami Znati ◽

Rebecca Carter ◽

Marcos Vasquez ◽

Adam Westhorpe ◽

Hassan Shahbakhti ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Combination Therapy ◽

Cell Lines ◽

Radiation Treatment ◽

Combined Treatment ◽

New Combination ◽

Migration And Invasion ◽

Syngeneic Mouse Model

Hepatocellular Carcinoma (HCC) is increasing in incidence worldwide and requires new approaches to therapy. The combination of anti-angiogenic drug therapy and radiotherapy is one promising new approach. The anti-angiogenic drug vandetanib is a tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) and RET proto-oncogene with radio-enhancement potential. To explore the benefit of combined vandetanib and radiotherapy treatment for HCC, we studied outcomes following combined treatment in pre-clinical models. Methods: Vandetanib and radiation treatment were combined in HCC cell lines grown in vitro and in vivo. In addition to 2D migration and clonogenic assays, the combination was studied in 3D spheroids and a syngeneic mouse model of HCC. Results: Vandetanib IC 50 s were measured in 20 cell lines and the drug was found to significantly enhance radiation cell kill and to inhibit both cell migration and invasion in vitro. In vivo, combination therapy significantly reduced cancer growth and improved overall survival, an effect that persisted for the duration of vandetanib treatment. Conclusion: In 2D and 3D studies in vitro and in a syngeneic model in vivo, the combination of vandetanib plus radiotherapy was more efficacious than either treatment alone. This new combination therapy for HCC merits evaluation in clinical trials.

Download Full-text